Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Von Hippel-Lindau disease].

M Los1, T P Links, J W Lenders

  • 1Afd. Interne Geneeskunde, Academisch Ziekenhuis, Utrecht.

Nederlands Tijdschrift Voor Geneeskunde
|March 29, 2000
PubMed
Summary

Von Hippel-Lindau (VHL) disease is an inherited cancer syndrome. Early detection and treatment of VHL-associated tumors, particularly in the eye and kidney, significantly improve patient prognosis and quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Von Hippel-Lindau disease: pathophysiological and clinical advances.

Familial cancer·2026
Same author

Thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer: interpretation, challenges, and future perspectives.

Journal of molecular endocrinology·2026
Same author

Prospective evaluation of genomics-guided off-label treatment.

Nature·2026
Same author

Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer.

Journal of gastrointestinal cancer·2025
Same author

Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy.

ESMO open·2025

Area of Science:

  • Oncology
  • Genetics
  • Nephrology

Background:

  • Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited cancer syndrome.
  • It predisposes individuals to various tumors, including renal cell carcinoma, pheochromocytoma, and pancreatic neuroendocrine tumors.

Observation:

  • Three case histories illustrate the clinical spectrum and management challenges of VHL disease.
  • A 22-year-old woman presented with retinal angiomatosis and later developed renal carcinoma.
  • A 44-year-old man with a family history died from metastatic clear-cell renal carcinomas.
  • A 31-year-old man with a family history developed epididymal cystadenoma, followed by cerebral and renal neoplasms detected through routine screening.

Findings:

  • Early recognition of 'sporadic VHL-like' tumors is crucial for timely diagnosis.
  • Frequent screening and prompt treatment of VHL patients are essential for managing disease progression.
  • Nephron-sparing surgery is a key surgical approach for VHL-related kidney tumors.

Implications:

  • Early detection and treatment of asymptomatic tumors, especially in the eye and kidney, significantly enhance the prognosis and quality of life for VHL patients.
  • Systematic surveillance protocols and timely interventions are vital for individuals with VHL disease.
  • Understanding the VHL gene's role in tumor suppression informs therapeutic strategies for related cancers.

Related Experiment Videos